Patient‐reported outcomes and health‐related quality of life in effectiveness studies: pros and cons

Abstract

The importance of patient perspectives on disease impact and response to therapy is increasingly recognized. Patient-reported outcomes (PROs), including health-related quality of life (HRQL), provide information on the effectiveness of medical interventions that cannot be obtained using objective clinical measures. For drug development, PROs such as symptom questionnaires are accepted by the European Medicines Agency (EMEA) and US Food and Drug Administration (FDA) in the approval process. HRQL assessments can help to establish the niche for a new product to support marketing efforts. Utilities can also be derived from health outcomes measures for cost-effectiveness analyses required by health plans for granting drug reimbursement. Because they more closely reflect routine clinical care, effectiveness studies are often a superior setting than traditional randomized controlled trials (RCTs) for conducting comprehensive PRO assessments to determine the real-world impact of therapy on symptoms and other aspects of everyday life. Screening, quality of care, self-reported adherence to treatment, and patient monitoring are important potential applications of PROs in effectiveness studies. However, well-known limitations of effectiveness studies also apply to PROs; these sometimes include a lack of randomization, controls, and blinding. It may be difficult to obtain patient compliance and clinician assistance with PRO assessments in a real-world setting. PRO data may be biased by nonrandom patient dropout, errors in timing of PRO assessments, and the environment in which questionnaires are administered. Additionally, the drug development schedule often requires outcomes results before effectiveness studies can be conducted. Addressing these difficulties during study design and the use of short and targeted questionnaires will improve the usefulness and feasibility of PRO measures in effectiveness studies. Drug Dev.

Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs)

“…Despite the agreement on symptoms with highest prevalence rates (i.e., joint pain, vasomotor symptoms, loss of interest in sexual intercourse) pivotal trials report significantly lower rates [3,4]. Our results, thereby, confirm the presumption that PROs reveal a higher level of symptom burden than conventional pivotal clinical trials [11,12,25,26]. Ruhstaller et al [16] reported comparable results in their PRO-based study.…”

“…Regarding clinical practice, our findings emphasize the necessity of increased application of self-report instruments given that outcomes voiced by the patients provide essential information on treatment impact (e.g., pain intensity and pain relief) that are difficult to obtain from other sources [26]. Screening for self-reported data could minimize potential negative consequences of the patient attitudes toward their physician and/or symptom experience and could help identify the patients suffering from side-effects otherwise missed.…”

Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity

“…In addition to clinical measures, patient-reported outcomes (PROs) are important to understand the patient's perspective of disease (4,5). Most PROs used in clinical trials of psoriasis therapies, such as the Dermatology Life Quality Index (DLQI) (6) and Short Form 36 v2 Acute Health Survey (SF-36v2), assess the impact of psoriasis or illness in general on health-related quality of life.…”

Validity, reliability, and responsiveness of a new short Visual Simplified Respiratory Questionnaire (VSRQ©) for health-related quality of life assessment in chronic obstructive pulmonary disease

“…It is a promising tool for use in large reallife studies, epidemiological and phase IV studies, as well as in clinical practice. 7,40,47,48 However, further validation in specifi c studies is needed.…”